BeiGene’s Phase III Trial of Zanubrutinib Misses Late-Stage Goals in Waldenström’s Macroglobulinemia
The Celgene trial was the first to demonstrate a benefit in the front-line setting for patients who are ineligible for intensive chemotherapy.
Biogen confirmed that high doses of aducanumab reduced clinical decline in its EMERGE trial.
A large-scale clinical study of 1,700 patients showed ubrogepant to be effective at easing pain and light or sound sensitivity as well as providing nausea relief.
Libella Gene Therapeutics has received approval from an institutional review board (IRB) to conduct a clinical trial in Colombia of a gene therapy intended to treat and reverse ageing.
Evolution Research Group (ERG) and Konica Minolta’s Invicro have collaborated to provide early-to-late-phase clinical research services for biotech and pharma sponsors.
Therapix Biosciences has announced that investigational drug THX-110 yielded favourable data in a Phase IIa clinical trial involving adults with obstructive sleep apnea (OSA).
Looking at depression clinical trials in the database with a start date from 2015 to present, 2018 had the most clinical trials.
Novartis and Incyte have reported positive results from the Phase III REACH2 clinical trial of Jakavi (ruxolitinib) conducted in steroid-refractory acute graft-versus-host disease (GvHD) patients.
The US National Institute on Alcohol Abuse’s AM-3506 and Sanofi’s SAR-411298 are both at the preclinical stage of development for PTSD.